Search Within

Kazunori Murata

Formats
  1. Journal Article (21)
  2. Meeting Abstract (8)
  3. Book Section (4)
Groups
  1. Department of Pathology and Laboratory Medicine (33)
  2. Department of Medicine (21)
  3. Hematologic Malignancies, Division of (20)
  4. Center for Hematologic Malignancies (19)
  5. Hematologic Malignancies Research (16)
  6. Myeloma (16)

More Groups

People
  1. Lakshmi Ramanathan (15)
  2. Carl Landgren (13)
  3. David Chung (12)
  4. Heather Landau (12)
  5. Sergio Giralt (12)
  6. Katie Thoren (11)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2022 (3)
  4. 2021 (7)
  5. 2020 (4)
  6. 2019 (4)

More Years

Publications
  1. Blood (7)
  2. Clinical Biochemistry (4)
  3. Blood Cancer Journal (2)
  4. Cancer Biomarkers: Clinical Aspects and Laboratory Determination (2)
  5. JAMA Oncology (2)
  6. Journal of Applied Laboratory Medicine (2)

More Publications

Publishers
  1. Elsevier Inc. (10)
  2. American Society of Hematology (8)
  3. Nature Publishing Group (3)
  4. Amer Assoc Clinical Chemistry (2)
  5. American Medical Association (2)
  6. Elsevier B.V. (1)

More Publishers

Results (33)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of plasma cell neoplasms
    Book Section

    Roshal, M.; Gao, Q.; Hutcherson, S.; Thoren, K.; Zhu, M.; Murata, K.
    In Schmitz, J. L.; Detrick, B.; O’Gorman, M. R. G. (Eds.) Manual of Molecular and Clinical Laboratory Immunology. 9th ed (2025)

    Fulltext@MSK | Save
  • Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
    Journal Article

    Firestone, R. S.; Socci, N. D.; Shekarkhand, T.; Zhu, M.; Qin, W. G.; Hultcrantz, M.; Mailankody, S.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
    Journal Article

    Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • PSA: Role in screening and monitoring patients with prostate cancer
    Book Section

    Carlsson, S. V.; Murata, K.; Danila, D. C.; Lilja, H.
    In Ramanathan, L. V.; Fleisher, M.; Duffy, M. J. (Eds.) Cancer Biomarkers: Clinical Aspects and Laboratory Determination (2022)

    Fulltext@MSK | Save
  • Chimeric antigen receptor T cells and management of toxicities: Implications of biomarkers
    Book Section

    Wudhikarn, K.; Alarcón Tomas, A.; Murata, K.; Perales, M. A.
    In Ramanathan, L. V.; Fleisher, M.; Duffy, M. J. (Eds.) Cancer Biomarkers: Clinical Aspects and Laboratory Determination (2022)

    Fulltext@MSK | Save
  • Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster
    Journal Article

    Zeig-Owens, R.; Goldfarb, D. G.; Luft, B. J.; Yang, X.; Murata, K.; Ramanathan, L.; Thoren, K.; Doddi, S.; Shah, U. A.; Mueller, A. K.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Use of a daratumumab-specific immunofixation assay to assess possible immunotherapy interference at a major cancer center: Our experience and recommendations
    Journal Article

    Kirchhoff, D. C.; Murata, K.; Thoren, K. L.
    Journal of Applied Laboratory Medicine (2021)

    Fulltext@MSK | Save
  • Immunotyping provides equivalent results to immunofixation in a population with a high prevalence of monoclonal gammopathies
    Journal Article

    Thoren, K. L.; McCash, S. I.; Murata, K.
    Journal of Applied Laboratory Medicine (2021)

    Fulltext@MSK | Save
  • Complex biological patterns of soluble cytokines and CD163 in childhood necessitating age-specific reference intervals for evidence-based clinical interpretation
    Journal Article

    Sepiashvili, L.; Alli, Z.; Bohn, M. K.; Hall, A.; Karin, A.; Murata, K.; Adeli, K.
    Clinical Biochemistry (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save